{"entity":{"id":"nct06640530","kind":"trial","name":"Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin","aka":["UNIVERSE"],"tldr":"A phase 3 trial of Nivolumab in melanoma, run by Biocad, active and no longer recruiting.","summary":"Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin is a phase 3 interventional study registered as NCT06640530 by Biocad, with 392 participants planned, started 2024-03-21 and due to reach its primary completion in 2025-12. Interventions recorded: BCD-263, Opdivo. Conditions listed: Advanced Melanoma, Melanoma (Skin). No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06640530","url":"https://clinicaltrials.gov/study/NCT06640530"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","advanced-melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["nivolumab"],"companies":["biocad"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06640530","phase":"3","setting":"A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin","sponsor":"Biocad","started":"2024-03-21","startedType":"actual","enrolled":392,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06640530/","neighbours":{"cancer":[{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"biocad","kind":"company","name":"Biocad","route":"/companies/biocad/"}]}}